Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
- Michael L. Wang, S. Rule, K. Blum
- MedicineNew England Journal of Medicine
- 7 August 2013
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
- D. Weber, Christine I. Chen, R. Knight
- MedicineNew England Journal of Medicine
- 22 November 2007
Lenalidomide plus dexamethasone is superior to placebo plus DexamethAsone in patients with relapsed or refractory multiple myeloma.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
- A. Stewart, S. Rajkumar, A. Palumbo
- MedicineNew England Journal of Medicine
- 2015
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- J. Abramson, M. Palomba, T. Siddiqi
- MedicineThe Lancet
- 1 September 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
- Michael L. Wang, J. Muñoz, P. Reagan
- MedicineNew England Journal of Medicine
- 1 April 2020
KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma, and led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies.
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
- Jennifer N Brudno, I. Maric, J. Kochenderfer
- Medicine, BiologyJournal of Clinical Oncology
- 29 May 2018
CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM and should encourage additional development of CAR T-cell therapies for MM.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
- D. Siegel, T. Martin, S. Jagannath
- MedicineBlood
- 4 October 2012
Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
- Y. Oki, M. Noorani, J. Westin
- MedicineBritish Journal of Haematology
- 1 September 2014
Multivariate analysis identified performance status ≥2 and bone marrow involvement as independent adverse prognostic factors for EFS and OS and further research is needed to identify predictive and/or targetable biological markers and novel therapeutic approaches for DHL patients.
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
- S. A. Ali, V. Shi, J. Kochenderfer
- Medicine, BiologyBlood
- 29 September 2016
The first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA demonstrates antimyeloma activity of CAR-BCMA T cells.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
- A. Goy, A. Younes, Alma M Rodriguez
- MedicineJournal of Clinical Oncology
- 1 February 2005
Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cells lymphomas and in combination with other cytotoxic or biologic agents.
...
...